[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 67, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 882000, "exercisedValue": 0, "unexercisedValue": 8921702}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 130576, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.4, "open": 10.46, "dayLow": 10.46, "dayHigh": 10.46, "regularMarketPreviousClose": 9.4, "regularMarketOpen": 10.46, "regularMarketDayLow": 10.46, "regularMarketDayHigh": 10.46, "beta": 0.022, "volume": 260, "regularMarketVolume": 260, "averageVolume": 15706, "averageVolume10days": 1940, "averageDailyVolume10Day": 1940, "bid": 9.25, "bidSize": 100, "fiftyTwoWeekLow": 0.99, "fiftyTwoWeekHigh": 14.67, "fiftyDayAverage": 10.21944, "twoHundredDayAverage": 4.555335, "currency": "USD", "floatShares": 29582975, "bookValue": 10.838, "priceToBook": 0.9651227, "netIncomeToCommon": -176936992, "52WeekChange": 3.3765693, "SandP52WeekChange": 0.23416412, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NAMSW", "underlyingSymbol": "NAMSW", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "072ede56-783e-317d-b7d9-5dc797a27eef", "messageBoardId": "finmb_685404834", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.46, "recommendationKey": "none", "totalCash": 340449984, "totalCashPerShare": 3.814, "ebitda": -182918000, "totalDebt": 60000, "quickRatio": 6.861, "currentRatio": 6.95, "totalRevenue": 14090000, "debtToEquity": 0.021, "revenuePerShare": 0.171, "returnOnAssets": -0.27702, "returnOnEquity": -0.49255002, "freeCashflow": -72001376, "operatingCashflow": -141218000, "revenueGrowth": 0.272, "grossMargins": 1.0, "operatingMargins": -27.779299, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-13"}]